Announcements Trials
Browse Landscape

Status

Completed 330Recruiting 282Active not recruiting 223Terminated 140Unknown 110Withdrawn 88Not yet recruiting 55Suspended 6Enrolling by invitation 2Temporarily not available 1No longer available 1

Sponsor Class

OTHER 1

Study Type

Expanded_access 1

Sponsor

Conditions

KRAS G12V Mutant Advanced Epithelial Cancers 1

Interventions

Insulin Infusion Systems 2Cyclophosphamide 2pembrolizumab 1fludarabine phosphate 1fludarabine 1Gemcitabine 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Temporarily not available × OTHER × pembrolizumab × Clear all
NCT05389514 2025-11-20

Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors

Providence Health & Services

Temporarily not available

KRAS G12V Mutant Advanced Epithelial Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡